Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

PHASE3TerminatedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

July 11, 2025

Study Completion Date

July 11, 2025

Conditions
Pyoderma Gangrenosum
Interventions
DRUG

vilobelimab

vilobelimab infusion

DRUG

Placebo

Placebo Infusion

Trial Locations (50)

3004

The Alfred Hospital, Melbourne, Melbourne

4032

Department of Dermatology, University of Debrecen, Debrecen

6720

Department of Dermatology and Allergology, University of Szeged, Szeged

19194

University of Pennsylvania, Philadelphia

20122

Fondazione IRCCS Ca´ Granda Ospedale Maggiore Policlinico SC Dermatologia, Milan

27516

University of North Carolina at Chapel Hill Department of Dermatology, Chapel Hill

28034

Hospital Ramón y Cajal, Madrid

30328

Advanced Medical Research, PC, Sandy Springs

31000

CHU Toulouse Hospital Larrey, Toulouse

32827

University of Central Florida College of Medicine, Orlando

33016

Aby´s New Generation Research, Inc, Hialeah

33146

Dermatology/University of Miami Hospital, Miami

33613

ForCare Clinical Research, Tampa

43215

Ohio State University Wexner Medical Cente OSU Dermatology West, Columbus

44093

CHU de Nantes - Clinique dermatologique, Nantes

44124

Apex Clinical Research Center, Mayfield Heights

44791

Catholic Clinic Bochum, Department of Dermatology, Bochum

56126

Ospedale Santa Chiara, Pisa

60590

Universitätsklinikum Frankfurt, Klinik für Dermatologie, Frankfurt am Main

69003

Hospital Edouard Herriot, Lyon

69120

Universitätsklinikum Heidelberg, Heidelberg

72076

Universitätshautklinik Tübingen, Tübingen

75010

Saint Louis Hospital, Paris

77401

The University of Texas Health Science Center at Houston, Bellaire

80337

Klinik und Poliklinik für Dermatologie und Allergologie, München

91054

Berge Hautklinik, Erlangen

97080

University Hospital Würzburg, Department of Dermatology, Würzburg

97239

Oregon Health and Science University, Portland

02115

Brigham and Women´s Hospital, Boston

Unknown

Premier Specialists, Kogarah

Veracity Clinical Research Pty Ltd as trustee for the MLS Trust, Brisbane

Liverpool Hospital, Sydney

Hôpitaux Universitaires de Bruxelles, Anderlecht

Cliniques Universitaires Saint-Luc, Brussels

University of Essen, Germany, Essen

Charité - Universitätsmedizin Berlin, Department of Dermatology, Venereology and Allergology, Berlin, Germany, Berlin

University clinic Duesseldorf Department of Dermatology Heinrich-Heine-University Duesseldorf, Düsseldorf

Universitätsklinik für Dermatologie und Venerologie der MLU Halle, Halle

Universitätsklinikum Hamburg-Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP), Hamburg

University Hospital Leipzig AöR, Leipzig

Department of Dermatology, Venerology and Oncodermatology, University of Pécs, Pécs

IRCCS Policlinico di Sant'Orsola Alma Mater Studiorum - University of Bologna, Bologna

AOU Città della salute e della scienza, Turin

Wojewódzki Specjalistyczny Szpital im. Dr Wł. Biegańskiego w Łodzi; Klinika Dermatologii, Dermatologii Dziecięcej i Onkologicznej Uniwersytetu Medycznego, Lodz

Department and Clinics of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin,, Lublin

Klinika Dermatologii, Chorób Przenoszonych Drogą Płciową i Immunologii Klininczej, Miejski Szpital Zespolony w Olsztynie Clinic of Dermatology,, Olsztyn

Państwowy Instytut Medyczny CSK MSWiA, Warsaw

City Clinic Przychodnia Lekarsko-Psychologiczna ul. Sliczna 13, Wroclaw, Poland, Wroclaw

Complejo Asistencial Universitario de Salamanca, Salamanca

University Hospital Basel Department of Dermatology at Universitäre Altersmedizin FELIX PLATTER, Basel

Sponsors

Lead Sponsor

All Listed Sponsors
lead

InflaRx GmbH

INDUSTRY

NCT05964413 - Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum | Biotech Hunter | Biotech Hunter